Home » Stocks » FPRX

Five Prime Therapeutics, Inc. (FPRX)

Stock Price: $37.76 USD 0.00 (0.00%)
Updated Mar 8, 2021 4:00 PM EST - Market closed
After-hours: $37.82 +0.06 (0.16%) Mar 8, 5:38 PM
Market Cap 1.74B
Revenue (ttm) 17.10M
Net Income (ttm) -94.83M
Shares Out 35.52M
EPS (ttm) -2.68
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 8
Last Price $37.76
Previous Close $37.76
Change ($) 0.00
Change (%) 0.00%
Day's Open 37.80
Day's Range 37.13 - 37.95
Day's Volume 6,797,777
52-Week Range 1.75 - 38.18

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 10 hours ago

Five Prime Therapeutics (FPRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

PRNewsWire - 2 days ago

NEW YORK, March 5, 2021 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities...

Zacks Investment Research - 3 days ago

Five Prime Therapeutics (FPRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into fu...

PRNewsWire - 4 days ago

NEW YORK, March 4, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Five Prime Therapeutics, Inc....

PRNewsWire - 4 days ago

MILWAUKEE, March 4, 2021 /PRNewswire/ -- Ademi LLP is investigating Five Prime (NASDAQ: FPRX) for possible breaches of fiduciary duty and other violations of law in its transaction with Amgen....

The Motley Fool - 4 days ago

The big biotech wants to bolster its late-stage pipeline with a potential new stomach cancer treatment.

Other stocks mentioned: AMGN
The Motley Fool - 4 days ago

Amgen is paying a premium to buy the small biotech.

Other stocks mentioned: AMGN
InvestorPlace - 4 days ago

Five Prime Therapeutics (FPRX) stock is soaring higher on Thursday following news that Amgen (AMGN) is acquiring the company. The post FPRX Stock: The Huge Takeover News That Has Five Prime Th...

Other stocks mentioned: AMGN
Benzinga - 4 days ago

Amgen Inc (NASDAQ: AMGN) has agreed to acquire Five Prime Therapeutics Inc (NASDAQ: FPRX) for $38 per share in cash, representing an equity value of approximately $1.9 billion. The offer price...

Other stocks mentioned: AMGN
Business Wire - 4 days ago

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Five Prime Therapeutics, Inc. (NASDAQ: FPRX) to Amgen Inc. for $38.00 per s...

Investors Business Daily - 4 days ago

Amgen said Thursday it will spend $1.9 billion to buy Five Prime Therapeutics, a small biotech company with a promising stomach cancer drug. The news sent FPRX stock rocketing.

Other stocks mentioned: AMGN
Business Wire - 4 days ago

THOUSAND OAKS, Calif. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--AMGEN TO ACQUIRE FIVE PRIME THERAPEUTICS FOR $1.9 BILLION IN CASH

Other stocks mentioned: AMGN
Zacks Investment Research - 5 days ago

Five Prime Therapeutics (FPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire - 6 days ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics Announces Timing of Its Fourth Quarter 2020 and Full Year Results Conference Call

Business Wire - 1 week ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics to Participate in the Cowen 41st Annual Health Care Conference

Business Wire - 2 weeks ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics to Participate in the SVB Leerink 10th Annual Global Healthcare Conference

Business Wire - 1 month ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics to Participate in Guggenheim Healthcare Talks 2021: Oncology Day

Seeking Alpha - 2 months ago

Overview of Five Prime Therapeutics.

The Motley Fool - 3 months ago

This tiny biotech might be developing a major new cancer drug.

The Motley Fool - 3 months ago

Biotech investors had more than just vaccines to think about this year.

Other stocks mentioned: CRDF, MRSN, SURF, TRIL
The Motley Fool - 3 months ago

There are plenty of healthcare stocks that have seen share growth this year. Here are three lesser-known stocks that have the potential to continue that growth this month and beyond.

Other stocks mentioned: WST, FLGT
Seeking Alpha - 3 months ago

Five Prime Therapeutics declared outstanding results last month and went up nearly 400%. Given the market potential, there may still be considerable upside.

Business Wire - 3 months ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Announces Closing of Upsized Public Offering of Common Stock

The Motley Fool - 3 months ago

Aptose Biosciences and Five Prime Therapeutics both have explosive growth potential.

Other stocks mentioned: APTO
Business Wire - 3 months ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics, Inc. (Nasdaq: FPRX), announced today the pricing of an underwritten public offering of 7,200,000 shares of its common sto...

Investors Business Daily - 3 months ago

Five Prime Therapeutics stock popped for a second day running Thursday after the small biotech company unveiled promising preclinical data for an experimental cancer treatment. The post Small ...

Zacks Investment Research - 3 months ago

Investors need to pay close attention to Five Prime (FPRX) stock based on the movements in the options market lately.

Pulse2 - 3 months ago

The stock price of Five Prime Therapeutics Inc (NASDAQ: FPRX) has increased by 237.08% on Wednesday. These are the details.

Business Wire - 3 months ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Announces Proposed Public Offering of Common Stock

The Motley Fool - 3 months ago

And as a bonus, find out which much-loved stock let its shareholders down.

InvestorPlace - 3 months ago

Shares of FPRX stock are skyrocketing on Wednesday after the company reported positive results from its stomach cancer treatment trial. The post Five Prime Therapeutics: 6 Things for FPRX Stoc...

InvestorPlace - 3 months ago

With the pandemic drawing much attention toward biotech stocks, there are some interesting ideas among in the small-cap field, but only if you understand the severe risks involved. The post 7 ...

Other stocks mentioned: CANF, GTBP, IFRX, TNXP, VTVT, VXRT
24/7 Wall Street - 3 months ago

Five Prime Therapeutics Inc. (NASDAQ: FPRX) shares more than tripled on Wednesday after the company announced positive topline results from its gastric cancer study.

Investors Business Daily - 3 months ago

Shares of Five Prime Therapeutics skyrocketed early Wednesday after the tiny biotech stock's stomach cancer treatment, a drug known as bemarituzumab, passed muster in a midstage test. The post...

Benzinga - 3 months ago

Five Prime Therapeutics Inc (NASDAQ: FPRX) shares are seeing astronomical gains Wednesday in reaction to a positive data readout. What Happened: Bemarituzumab, a targeted therapy, in combinati...

Business Insider - 3 months ago

A potential breakthrough in the treatment of stomach cancer helped boost shares of Five Prime Therapeutics higher by as much as 386% to $26.00 in Tuesday pre-market trades. The small-cap biote...

The Motley Fool - 3 months ago

The biotech's stomach cancer drug hit the mark in a midstage trial.

Market Watch - 3 months ago

Shares of Five Prime Therapeutics Inc. blasted 353% higher on heavy volume toward a three-year high in premarket trading Wednesday, after the company said its treatment for gastric cancer met ...

Market Watch - 3 months ago

Shares of Five Prime Therapeutics Inc. blasted 314% higher in premarket trading Wednesday, after the company said its treatment for gastric cancer met all three of its efficacy endpoints from ...

Seeking Alpha - 4 months ago

Five Prime Therapeutics, Inc. (FPRX) CEO Tom Civik on Q3 2020 Results - Earnings Call Transcript

Seeking Alpha - 4 months ago

Five Prime Therapeutics, Inc. (FPRX) CEO Tom Civik on Q3 2020 Results - Quick Version Earnings Call Transcript

Zacks Investment Research - 4 months ago

Five Prime Therapeutics (FPRX) delivered earnings and revenue surprises of -21.31% and -41.49%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead...

Benzinga - 4 months ago

Shares of Five Prime Therapeutics (NASDAQ:FPRX) were unchanged in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share increased 28.16% over the pas...

Business Wire - 4 months ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics Reports Third Quarter 2020 Results

Zacks Investment Research - 4 months ago

Five Prime Therapeutics (FPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire - 4 months ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics Announces Timing of Its Third Quarter 2020 Results Conference Call

Zacks Investment Research - 4 months ago

Five Prime (FPRX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Business Wire - 5 months ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics to Participate in the 2020 Wells Fargo Virtual Healthcare Conference

Seeking Alpha - 6 months ago

Five Prime Therapeutics, Inc. (FPRX) CEO Tom Civik on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 7 months ago

Five Prime Therapeutics (FPRX) delivered earnings and revenue surprises of 31.43% and -22.76%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for t...

About FPRX

Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase 3 clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that is in Phase 1a/1b clinical trial that targets B7-H4 in various cancers, as well as FPT155, a solub... [Read more...]

Industry
Biotechnology
IPO Date
Sep 18, 2013
CEO
Thomas Civik
Employees
87
Stock Exchange
NASDAQ
Ticker Symbol
FPRX
Full Company Profile

Financial Performance

In 2019, FPRX's revenue was $14.87 million, a decrease of -70.17% compared to the previous year's $49.87 million. Losses were -$137.20 million, -2.31% less than in 2018.

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for FPRX stock is "Strong Buy." The 12-month stock price forecast is 35.67, which is a decrease of -5.53% from the latest price.

Price Target
$35.67
(-5.53% downside)
Analyst Consensus: Strong Buy